You are here: Industry Insights > X4 Pharmaceuticals

News List

X4 Pharmaceuticals Completes Merger with Arsanis pharmaceutical-technology
March 14, 2019
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the completion of its merger with Arsanis, Inc., effective as of March 13, 2019.
X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P-001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial pharmafocusasia
December 03, 2018
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer...
X4 Pharmaceuticals signs agreement to merge with Arsanis subsidiary pharmaceutical-technology
November 30, 2018
X4 Pharmaceuticals has signed a definitive agreement to merge with a wholly owned subsidiary of Arsanis in an all-stock transaction.....
Arsanis and X4 Pharmaceuticals Announce Merger americanpharmaceuticalreview
November 28, 2018
Arsanis and privately-held X4 Pharmaceuticals have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary .....
X4 Pharma appoints Michael Wyzga as Chair of Board of Directors biospectrumasia
July 16, 2018
Mr. Wyzga brings leadership experience, including in rare diseases and cancer.
X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity biospace
April 17, 2018
X4 Pharmaceuticals,today highlighted data from a presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting.